Actualités et synthèse du traitement de seconde ligne des CBNPC de stade IV sans addiction oncogénique

Read full text Summarise with VIRAT
Authors: Thomas Pierret, R. Descourt, R. Corre, Pascale Tomasini, Chantal Decroisette
Cited by: 0
References: 35

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Stage IV non-small cell lung cancer (NSCLC) without actionable mutations remains a major therapeutic challenge, especially following immunotherapy failure. The introduction of immune checkpoint inhibitors (anti-PD-1/PD-L1) has revolutionized first-line treatment, but second-line options remain largely dependent on older chemotherapies such as docetaxel or pemetrexed. A significant number of patients experience disease progression despite immunotherapy, highlighting tumor resistance mechanisms, whether primary (rapid failure) or acquired (after initial response). Resistance mechanisms include low CD8+ T-cell infiltration, genetic mutations (PTEN, JAK), loss of neoantigens, and tumor-induced immunosuppression. Innovative strategies are under investigation: antibody-drug conjugates (anti-TROP-2, anti-CEACAM-5), cancer vaccines (TEDOPI), external electric fields (TTFields), oncolytic viruses, and PROTACs. While some of these show promise in progression-free survival, global survival benefit remains modest. The identification of robust predictive biomarkers is essential for tailoring future therapies.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Bulletin du Cancer
Volume
113
Issue
5
Pages
654–663
Publication date
19 March 2026
Language
FR